argenex SE $ARGX Shares Purchased by Woodline Partners LP

Key Points

• Woodline Partners LP increased its stake in argenex SE by 21.0%, now owning approximately 0.15% of the company, worth $53.15 million.
• Institutional investors collectively own 60.32% of argenex's stock, with significant positions held by RTW Investments LP and Millennium Management LLC, which both reported substantial increases in their holdings.
• Analysts have a consensus Buy rating for argenex, with several raising their price targets, with Bank of America setting a target of $887.00.

Woodline Partners LP raised its holdings in shares of argenex SE (NASDAQ:ARGX - Free Report) by 21.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 89,796 shares of the company's stock after acquiring an additional 15,559 shares during the period. Woodline Partners LP owned approximately 0.15% of argenex worth $53,147,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Point72 Europe London LLP acquired a new position in argenex in the fourth quarter valued at approximately $5,839,000. Ameriprise Financial Inc. increased its holdings in argenex by 10.0% in the 4th quarter. Ameriprise Financial Inc. now owns 7,013 shares of the company's stock worth $4,313,000 after acquiring an additional 639 shares in the last quarter. Sowell Financial Services LLC purchased a new stake in argenex in the 1st quarter worth $332,000. Cetera Investment Advisers increased its holdings in argenex by 33.1% in the 1st quarter. Cetera Investment Advisers now owns 5,491 shares of the company's stock worth $3,250,000 after acquiring an additional 1,364 shares in the last quarter. Finally, Quantbot Technologies LP raised its holdings in shares of argenex by 4,533.3% during the first quarter. Quantbot Technologies LP now owns 139 shares of the company's stock valued at $82,000 after acquiring an additional 136 shares during the last quarter. 60.32% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have commented on ARGX. Wedbush reissued an "outperform" rating and set a $800.00 target price on shares of argenex in a report on Monday, August 25th. Bank of America increased their target price on argenex from $880.00 to $887.00 and gave the company a "buy" rating in a report on Tuesday, September 2nd. Wells Fargo & Company boosted their target price on argenex from $741.00 to $756.00 and gave the stock an "overweight" rating in a report on Thursday, July 31st. Morgan Stanley boosted their target price on argenex from $700.00 to $766.00 and gave the stock an "overweight" rating in a report on Friday, August 1st. Finally, Jefferies Financial Group set a $818.00 target price on argenex and gave the stock a "buy" rating in a report on Tuesday, August 26th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat, argenex presently has a consensus rating of "Buy" and a consensus target price of $772.84.

argenex Stock Performance

Shares of NASDAQ ARGX traded down $7.14 during midday trading on Friday, reaching $756.38. 339,273 shares of the stock were exchanged, compared to its average volume of 376,537. The company has a 50 day simple moving average of $645.47 and a 200 day simple moving average of $606.10. The stock has a market capitalization of $46.29 billion, a P/E ratio of 38.79, a PEG ratio of 0.81 and a beta of 0.41. argenex SE has a twelve month low of $510.05 and a twelve month high of $779.03.

argenex (NASDAQ:ARGX - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The company reported $3.74 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.84 by $0.90. The business had revenue of $866.79 million during the quarter, compared to the consensus estimate of $776.82 million. argenex had a net margin of 40.98% and a return on equity of 21.06%. On average, research analysts expect that argenex SE will post 3.13 earnings per share for the current year.

argenex Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.